mRNA vaccine effectiveness against hospitalisation due to severe acute respiratory infection (SARI) COVID-19 during Omicron variant predominance estimated from real-world surveillance data, Slovenia, February to March 2022

For the period of predominance of SARS-CoV-2 Omicron variant in Slovenia, February to March 2022, we estimated mRNA vaccine effectiveness (VE) against severe acute respiratory infection (SARI) COVID-19 using surveillance data. In the most vulnerable age group comprising individuals aged 65 years and...

Descripción completa

Detalles Bibliográficos
Autores principales: Grgič Vitek, Marta, Klavs, Irena, Učakar, Veronika, Vrh, Marjana, Mrzel, Maja, Serdt, Mojca, Fafangel, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2022
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121658/
https://www.ncbi.nlm.nih.gov/pubmed/35593166
http://dx.doi.org/10.2807/1560-7917.ES.2022.27.20.2200350
_version_ 1784711197406265344
author Grgič Vitek, Marta
Klavs, Irena
Učakar, Veronika
Vrh, Marjana
Mrzel, Maja
Serdt, Mojca
Fafangel, Mario
author_facet Grgič Vitek, Marta
Klavs, Irena
Učakar, Veronika
Vrh, Marjana
Mrzel, Maja
Serdt, Mojca
Fafangel, Mario
author_sort Grgič Vitek, Marta
collection PubMed
description For the period of predominance of SARS-CoV-2 Omicron variant in Slovenia, February to March 2022, we estimated mRNA vaccine effectiveness (VE) against severe acute respiratory infection (SARI) COVID-19 using surveillance data. In the most vulnerable age group comprising individuals aged 65 years and more, VE against SARI COVID-19 was 95% (95% CI: 95–96%) for those vaccinated with three doses, in comparison to 82% (95% CI: 79–84%) for those vaccinated with two doses. Such levels of protection were maintained for at least 6 months.
format Online
Article
Text
id pubmed-9121658
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher European Centre for Disease Prevention and Control (ECDC)
record_format MEDLINE/PubMed
spelling pubmed-91216582022-06-13 mRNA vaccine effectiveness against hospitalisation due to severe acute respiratory infection (SARI) COVID-19 during Omicron variant predominance estimated from real-world surveillance data, Slovenia, February to March 2022 Grgič Vitek, Marta Klavs, Irena Učakar, Veronika Vrh, Marjana Mrzel, Maja Serdt, Mojca Fafangel, Mario Euro Surveill Rapid Communication For the period of predominance of SARS-CoV-2 Omicron variant in Slovenia, February to March 2022, we estimated mRNA vaccine effectiveness (VE) against severe acute respiratory infection (SARI) COVID-19 using surveillance data. In the most vulnerable age group comprising individuals aged 65 years and more, VE against SARI COVID-19 was 95% (95% CI: 95–96%) for those vaccinated with three doses, in comparison to 82% (95% CI: 79–84%) for those vaccinated with two doses. Such levels of protection were maintained for at least 6 months. European Centre for Disease Prevention and Control (ECDC) 2022-05-19 /pmc/articles/PMC9121658/ /pubmed/35593166 http://dx.doi.org/10.2807/1560-7917.ES.2022.27.20.2200350 Text en This article is copyright of the authors or their affiliated institutions, 2022. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
spellingShingle Rapid Communication
Grgič Vitek, Marta
Klavs, Irena
Učakar, Veronika
Vrh, Marjana
Mrzel, Maja
Serdt, Mojca
Fafangel, Mario
mRNA vaccine effectiveness against hospitalisation due to severe acute respiratory infection (SARI) COVID-19 during Omicron variant predominance estimated from real-world surveillance data, Slovenia, February to March 2022
title mRNA vaccine effectiveness against hospitalisation due to severe acute respiratory infection (SARI) COVID-19 during Omicron variant predominance estimated from real-world surveillance data, Slovenia, February to March 2022
title_full mRNA vaccine effectiveness against hospitalisation due to severe acute respiratory infection (SARI) COVID-19 during Omicron variant predominance estimated from real-world surveillance data, Slovenia, February to March 2022
title_fullStr mRNA vaccine effectiveness against hospitalisation due to severe acute respiratory infection (SARI) COVID-19 during Omicron variant predominance estimated from real-world surveillance data, Slovenia, February to March 2022
title_full_unstemmed mRNA vaccine effectiveness against hospitalisation due to severe acute respiratory infection (SARI) COVID-19 during Omicron variant predominance estimated from real-world surveillance data, Slovenia, February to March 2022
title_short mRNA vaccine effectiveness against hospitalisation due to severe acute respiratory infection (SARI) COVID-19 during Omicron variant predominance estimated from real-world surveillance data, Slovenia, February to March 2022
title_sort mrna vaccine effectiveness against hospitalisation due to severe acute respiratory infection (sari) covid-19 during omicron variant predominance estimated from real-world surveillance data, slovenia, february to march 2022
topic Rapid Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121658/
https://www.ncbi.nlm.nih.gov/pubmed/35593166
http://dx.doi.org/10.2807/1560-7917.ES.2022.27.20.2200350
work_keys_str_mv AT grgicvitekmarta mrnavaccineeffectivenessagainsthospitalisationduetosevereacuterespiratoryinfectionsaricovid19duringomicronvariantpredominanceestimatedfromrealworldsurveillancedatasloveniafebruarytomarch2022
AT klavsirena mrnavaccineeffectivenessagainsthospitalisationduetosevereacuterespiratoryinfectionsaricovid19duringomicronvariantpredominanceestimatedfromrealworldsurveillancedatasloveniafebruarytomarch2022
AT ucakarveronika mrnavaccineeffectivenessagainsthospitalisationduetosevereacuterespiratoryinfectionsaricovid19duringomicronvariantpredominanceestimatedfromrealworldsurveillancedatasloveniafebruarytomarch2022
AT vrhmarjana mrnavaccineeffectivenessagainsthospitalisationduetosevereacuterespiratoryinfectionsaricovid19duringomicronvariantpredominanceestimatedfromrealworldsurveillancedatasloveniafebruarytomarch2022
AT mrzelmaja mrnavaccineeffectivenessagainsthospitalisationduetosevereacuterespiratoryinfectionsaricovid19duringomicronvariantpredominanceestimatedfromrealworldsurveillancedatasloveniafebruarytomarch2022
AT serdtmojca mrnavaccineeffectivenessagainsthospitalisationduetosevereacuterespiratoryinfectionsaricovid19duringomicronvariantpredominanceestimatedfromrealworldsurveillancedatasloveniafebruarytomarch2022
AT fafangelmario mrnavaccineeffectivenessagainsthospitalisationduetosevereacuterespiratoryinfectionsaricovid19duringomicronvariantpredominanceestimatedfromrealworldsurveillancedatasloveniafebruarytomarch2022

Ejemplares similares